CY1105120T1 - Η αντιμετωπιση αναπνευστικων νοσων - Google Patents

Η αντιμετωπιση αναπνευστικων νοσων

Info

Publication number
CY1105120T1
CY1105120T1 CY20061101079T CY061101079T CY1105120T1 CY 1105120 T1 CY1105120 T1 CY 1105120T1 CY 20061101079 T CY20061101079 T CY 20061101079T CY 061101079 T CY061101079 T CY 061101079T CY 1105120 T1 CY1105120 T1 CY 1105120T1
Authority
CY
Cyprus
Prior art keywords
treatment
respiratory diseases
glycopyrrolate
exerts
administration
Prior art date
Application number
CY20061101079T
Other languages
English (en)
Inventor
Robin Mark Bannister
Andrew John Mcglashan Richards
Julian Clive Gilbert
David A. V. Morton
John Staniforth
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105120(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of CY1105120T1 publication Critical patent/CY1105120T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Μία φαρμακευτική σύνθεση για πνευμονική διανομή περιλαμβάνει γλυκοπυρρολικό σε μία μορφοποίηση ελεγχόμενης αποδέσμευσης, όπου, κατά τη χορήγηση, το γλυκοπυρρολικό ασκεί τη φαρμακολογική του επίδραση επί περίοδο μεγαλύτερη από 12 ώρες.
CY20061101079T 2000-04-07 2006-07-31 Η αντιμετωπιση αναπνευστικων νοσων CY1105120T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
CY1105120T1 true CY1105120T1 (el) 2010-03-03

Family

ID=9889490

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101079T CY1105120T1 (el) 2000-04-07 2006-07-31 Η αντιμετωπιση αναπνευστικων νοσων

Country Status (25)

Country Link
US (3) US7229607B2 (el)
EP (3) EP2193791A1 (el)
JP (1) JP5042426B2 (el)
CN (3) CN101181263B (el)
AT (1) ATE330585T2 (el)
AU (2) AU2004242450B2 (el)
BE (1) BE2013C023I2 (el)
BR (1) BR0109875A (el)
CA (1) CA2405705C (el)
CY (1) CY1105120T1 (el)
DE (1) DE60120936T3 (el)
DK (1) DK1267866T4 (el)
ES (2) ES2687751T3 (el)
GB (1) GB0008660D0 (el)
HK (1) HK1050846B (el)
HU (2) HU230958B1 (el)
IL (2) IL151791A0 (el)
LU (2) LU92166I2 (el)
MX (1) MXPA02009718A (el)
NO (3) NO336142B1 (el)
NZ (2) NZ521476A (el)
PL (1) PL364024A1 (el)
PT (1) PT1267866E (el)
WO (1) WO2001076575A2 (el)
ZA (1) ZA200207420B (el)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
DE60140268D1 (de) 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
WO2002094320A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
ES2779273T3 (es) * 2002-03-01 2020-08-14 Chiesi Farm Spa Formulación superfina de formoterol
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
NZ548302A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
CN100569235C (zh) 2004-02-06 2009-12-16 Meda制药有限及两合公司 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
CA2552458A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
AU2005221151A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006003078A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
JP4991693B2 (ja) 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
ES2330047T3 (es) 2005-12-21 2009-12-03 MEDA PHARMA GMBH & CO. KG Combinacion de r,r-glicopirrolato, rolipram y budesonida para el tratmiento de enfermedades inflamatorias.
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
AU2008334547B2 (en) * 2007-12-13 2011-06-30 Novartis Ag Organic compounds
CA2708083C (en) * 2007-12-13 2016-06-28 Novartis Ag Organic compounds
WO2009134524A2 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2400950B1 (en) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US20110132357A1 (en) 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EA021917B1 (ru) 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия астмы и copd
EP2515854B1 (en) 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Aerosol formualtion for COPD
RU2561052C2 (ru) 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
EP2515856B1 (en) 2009-12-23 2014-04-02 Chiesi Farmaceutici S.p.A. Aerosol Formulation for COPD
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN103841960B (zh) 2011-08-01 2017-07-07 莫纳什大学 用于吸入的方法和制剂
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
MX368835B (es) 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
US10532041B2 (en) 2014-09-09 2020-01-14 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
EP3494962B1 (en) * 2014-09-15 2021-05-26 Verona Pharma PLC Liquid inhalation formulation comprising rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
AU2016279798B2 (en) * 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
KR20220108047A (ko) 2019-12-02 2022-08-02 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
AU745331B2 (en) * 1996-11-11 2002-03-21 Meda Pharma Gmbh & Co. Kg Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
EP0954282B1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
WO2000006121A1 (de) * 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
EP2266548B1 (de) * 1998-11-13 2020-05-20 Jagotec AG Trockenpulver zur inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) * 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 Henkel IP & Holding GmbH 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
AU2010200660B2 (en) 2012-04-19
DK1267866T3 (da) 2006-10-23
EP1267866B1 (en) 2006-06-21
AU2010200660A1 (en) 2010-03-11
LU92393I2 (fr) 2015-11-02
PL364024A1 (en) 2004-11-29
EP1449528B1 (en) 2018-08-08
NO20024708L (no) 2002-10-24
ES2266242T3 (es) 2007-03-01
CA2405705C (en) 2011-06-07
NO2015024I2 (no) 2015-11-25
PT1267866E (pt) 2006-10-31
DE60120936D1 (de) 2006-08-03
EP1267866B2 (en) 2016-07-20
CN1720995A (zh) 2006-01-18
HU230958B1 (hu) 2019-06-28
CN101181263A (zh) 2008-05-21
JP2003530344A (ja) 2003-10-14
EP2193791A1 (en) 2010-06-09
CN1292745C (zh) 2007-01-03
US20050019271A1 (en) 2005-01-27
BR0109875A (pt) 2004-07-20
EP1267866A2 (en) 2003-01-02
US20080220073A1 (en) 2008-09-11
IL151791A (en) 2015-05-31
JP5042426B2 (ja) 2012-10-03
US7368104B2 (en) 2008-05-06
GB0008660D0 (en) 2000-05-31
IL151791A0 (en) 2003-04-10
NZ521476A (en) 2004-10-29
DK1267866T4 (en) 2016-10-03
NO20024708D0 (no) 2002-10-01
CN1422154A (zh) 2003-06-04
CA2405705A1 (en) 2001-10-18
US7229607B2 (en) 2007-06-12
AU2004242450A1 (en) 2005-01-20
MXPA02009718A (es) 2003-05-27
DE60120936T2 (de) 2006-11-02
HK1050846B (zh) 2007-01-26
AU776913B2 (en) 2004-09-23
WO2001076575A3 (en) 2002-03-28
ZA200207420B (en) 2003-09-16
ES2687751T3 (es) 2018-10-29
NO336142B1 (no) 2015-05-26
US8029768B2 (en) 2011-10-04
AU2004242450B2 (en) 2010-06-03
CN101181263B (zh) 2011-07-06
ATE330585T2 (de) 2006-07-15
BE2013C023I2 (el) 2020-06-24
HK1050846A1 (en) 2003-07-11
HUP0301518A2 (hu) 2003-08-28
NZ535284A (en) 2006-04-28
NO2015025I1 (no) 2015-12-07
EP1449528A1 (en) 2004-08-25
WO2001076575A2 (en) 2001-10-18
HUS1900056I1 (hu) 2020-02-28
LU92166I2 (fr) 2014-03-13
AU8930601A (en) 2001-10-23
ES2266242T5 (es) 2016-10-04
US20030068280A1 (en) 2003-04-10
NO2015024I1 (no) 2015-11-25
DE60120936T3 (de) 2016-11-17

Similar Documents

Publication Publication Date Title
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
CY1105000T1 (el) Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
BR0015188A (pt) Composições farmacêuticas
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
PT998287E (pt) Utilizacao de levobupivacaina
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE360428T1 (de) Analgetisches arzneimittel
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE0001916D0 (sv) Novel formulation
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
ATE402719T1 (de) Injiziebare pharmazeutische zusammensetzung enthaltend ethanol zur behandlung von bandscheibenvorfällen